Endocrine Abstracts

This study aimed to determine if berberine (BBR) or pioglitazone (PGZ) is more effective and safer for treating people with type 2 diabetes or non-alcoholic fatty liver disease (NAFLD). 184 people with NAFLD and impaired glucose metabolism were randomly allocated 16 weeks of lifestyle intervention (LI), LI plus PGZ (15mg daily) or LI plus BBR (1.5 g daily) as their course of treatment. We measured the levels of blood insulin, osteocalcin, C reactive protein (CRP), liver enzyme...